In last trading session, Avidity Biosciences Inc (NASDAQ:RNA) saw 1.42 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $28.40 trading at -$1.48 or -4.95% at ring of the bell on the day assigns it a market valuation of $3.42B. That closing price of RNA’s stock is at a discount of -97.18% from its 52-week high price of $56.00 and is indicating a premium of 24.26% from its 52-week low price of $21.51. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.65 million shares which gives us an average trading volume of 1.53 million if we extend that period to 3-months.
For Avidity Biosciences Inc (RNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.07. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.95 in the current quarter.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Upright in the red during last session for losing -4.95%, in the last five days RNA remained trading in the green while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $28.40 price level, adding 8.95% to its value on the day. Avidity Biosciences Inc’s shares saw a change of -2.34% in year-to-date performance and have moved 8.52% in past 5-day. Avidity Biosciences Inc (NASDAQ:RNA) showed a performance of 5.54% in past 30-days. Number of shares sold short was 15.58 million shares which calculate 8.83 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 54.5 to the stock, which implies a rise of 47.89% to its current value. Analysts have been projecting 50 as a low price target for the stock while placing it at a high target of 59. It follows that stock’s current price would drop -76.06% in reaching the projected high whereas dropping to the targeted low would mean a loss of -76.06% for stock’s current value.
Avidity Biosciences Inc (RNA) estimates and forecasts
This year revenue growth is estimated to fall -32.23% from the last financial year’s standing.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.61M for the same. And 10 analysts are in estimates of company making revenue of 1.61M in the next quarter. Company posted 2.04M and 2.34M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -34.37% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -36.54% while estimates for its earnings growth in next 5 years are of -1.72%.
Avidity Biosciences Inc (NASDAQ:RNA)’s Major holders
Insiders are in possession of 5.16% of company’s total shares while institution are holding 108.88 percent of that, with stock having share float percentage of 114.80%. Investors also watch the number of corporate investors in a company very closely, which is 108.88% institutions for Avidity Biosciences Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at RNA for having 16.16 million shares of worth $660.1 million. And as of 2024-06-30, it was holding 15.1121 of the company’s outstanding shares.
The second largest institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, which was holding about 10.92 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.2093 of outstanding shares, having a total worth of $445.94 million.
On the other hand, T. Rowe Price New Horizons Fund, Inc. and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 4.43 shares of worth $125.75 million or 3.67% of the total outstanding shares. The later fund manager was in possession of 3.54 shares on Mar 31, 2025 , making its stake of worth around $100.4 million in the company or a holder of 2.93% of company’s stock.
